Cancer Immune Escape: the Role of Antigen Presentation Machinery

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2023 Apr 9

PMID 37031434

Authors

Anoop Kallingal

Mateusz Olszewski

Natalia Maciejewska

Wioletta Brankiewicz

Maciej Baginski

Affiliations

Soon will be listed here.

Abstract

The mechanisms of antigen processing and presentation play a crucial role in the recognition and targeting of cancer cells by the immune system. Cancer cells can evade the immune system by downregulating or losing the expression of the proteins recognized by the immune cells as antigens, creating an immunosuppressive microenvironment, and altering their ability to process and present antigens. This review focuses on the mechanisms of cancer immune evasion with a specific emphasis on the role of antigen presentation machinery. The study of the immunopeptidome, or peptidomics, has provided insights into the mechanisms of cancer immune evasion and has potential applications in cancer diagnosis and treatment. Additionally, manipulating the epigenetic landscape of cancer cells plays a critical role in suppressing the immune response against cancer. Targeting these mechanisms through the use of HDACis, DNMTis, and combination therapies has the potential to improve the efficacy of cancer immunotherapy. However, further research is needed to fully understand the mechanisms of action and optimal use of these therapies in the clinical setting.

Citing Articles

Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer.

Vo M, Nguyen V, Tran V, Oh H, Jung S, Bae W Cancer Immunol Immunother. 2025; 74(4):143.

PMID: 40056167 PMC: 11890499. DOI: 10.1007/s00262-025-03997-2.

A single point mutation on FLT3L-Fc protein increases the risk of immunogenicity.

Qin D, Phung Q, Wu P, Yin Z, Tam S, Tran P Front Immunol. 2025; 16:1519452.

PMID: 40018031 PMC: 11865242. DOI: 10.3389/fimmu.2025.1519452.

Cancer brain metastasis: molecular mechanisms and therapeutic strategies.

Lu Y, Huang Y, Zhu C, Li Z, Zhang B, Sheng H Mol Biomed. 2025; 6(1):12.

PMID: 39998776 PMC: 11861501. DOI: 10.1186/s43556-025-00251-0.

Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction.

Verona F, Di Bella S, Schirano R, Manfredi C, Angeloro F, Bozzari G Front Immunol. 2025; 16:1529847.

PMID: 39981232 PMC: 11839637. DOI: 10.3389/fimmu.2025.1529847.

Conventional Chemotherapy and Inflammation: What Is the Role of the Inflammasome in the Tumor Microenvironment?.

Colarusso C, Terlizzi M, Di Caprio S, Falanga A, DAndria E, dEmmanuele di Villa Bianca R Biomedicines. 2025; 13(1).

PMID: 39857785 PMC: 11762891. DOI: 10.3390/biomedicines13010203.

References

Anderson N, Simon M . The tumor microenvironment. Curr Biol. 2020; 30(16):R921-R925. PMC: 8194051. DOI: 10.1016/j.cub.2020.06.081. View

Beatty G, Gladney W . Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2014; 21(4):687-92. PMC: 4334715. DOI: 10.1158/1078-0432.CCR-14-1860. View

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View

Blum J, Wearsch P, Cresswell P . Pathways of antigen processing. Annu Rev Immunol. 2013; 31:443-73. PMC: 4026165. DOI: 10.1146/annurev-immunol-032712-095910. View

Buchbinder E, Desai A . CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2015; 39(1):98-106. PMC: 4892769. DOI: 10.1097/COC.0000000000000239. View

Callahan M, Wolchok J, Allison J . Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010; 37(5):473-84. PMC: 3008567. DOI: 10.1053/j.seminoncol.2010.09.001. View

Dan H, Zhang S, Zhou Y, Guan Q . DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses. Onco Targets Ther. 2019; 12:10903-10916. PMC: 6913319. DOI: 10.2147/OTT.S217767. View

Dersh D, Holly J, Yewdell J . A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol. 2020; 21(2):116-128. DOI: 10.1038/s41577-020-0390-6. View

Fessas P, Lee H, Ikemizu S, Janowitz T . A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017; 44(2):136-140. PMC: 5612055. DOI: 10.1053/j.seminoncol.2017.06.002. View

10.

Filley A, Henriquez M, Dey M . CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors. Front Oncol. 2018; 8:453. PMC: 6199385. DOI: 10.3389/fonc.2018.00453. View

11.

Gibney E, Nolan C . Epigenetics and gene expression. Heredity (Edinb). 2010; 105(1):4-13. DOI: 10.1038/hdy.2010.54. View

12.

Gonzalez H, Hagerling C, Werb Z . Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32(19-20):1267-1284. PMC: 6169832. DOI: 10.1101/gad.314617.118. View

13.

Gryder B, Sodji Q, Oyelere A . Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012; 4(4):505-24. PMC: 3341130. DOI: 10.4155/fmc.12.3. View

14.

Han Y, Liu D, Li L . PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10(3):727-742. PMC: 7136921. View

15.

He X, Xu C . Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020; 30(8):660-669. PMC: 7395714. DOI: 10.1038/s41422-020-0343-4. View

16.

Hewitt E . The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology. 2003; 110(2):163-9. PMC: 1783040. DOI: 10.1046/j.1365-2567.2003.01738.x. View

17.

Hu C, Liu X, Zeng Y, Liu J, Wu F . DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics. 2021; 13(1):166. PMC: 8394595. DOI: 10.1186/s13148-021-01154-x. View

18.

Kulkarni B, Kirave P, Gondaliya P, Jash K, Jain A, Tekade R . Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer. Drug Discov Today. 2019; 24(10):2058-2067. DOI: 10.1016/j.drudis.2019.06.010. View

19.

Kunimasa K, Goto T . Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. Int J Mol Sci. 2020; 21(2). PMC: 7014343. DOI: 10.3390/ijms21020597. View

20.

Lao Y, Shen D, Zhang W, He R, Jiang M . Immune Checkpoint Inhibitors in Cancer Therapy-How to Overcome Drug Resistance?. Cancers (Basel). 2022; 14(15). PMC: 9331941. DOI: 10.3390/cancers14153575. View